Slide 1: CogState Investor Presentation August 2011
August 2011 For personal use only Brad O’Connor Chief Executive Officer boconnor@cogstate.com
Slide 2: CogState provides technology solutions for the assessment of thinking
CogState provides… For personal use only Technology solutions for the assessment of thinking in humans • Cashflow positive • Offices in Australia, USA & UK • Expertise in: - neuroscience - software development - large pharma operations ASX:CGS 2
Slide 3: Three Business Segments Provide Enhanced Opportunity
Three Business Segments Provide Enhanced Opportunity For personal use only Clinical Drug Concussion Dementia Screening Trials Management Description Quantify the effects Web-based test to assist Web-based test designed to of drugs on human in management of sports detect first signs of cognitive subj
Slide 4: Clinical Drug Trials
Clinical Drug Trials For personal use only • Cash flow positive business generating US$8m revenue p.a. and growing • Cognition testing is used in many clinical trials for drugs designed to work on central nervous system diseases and disorders – looking for both cognitive improvement (thinking more c
Slide 5: Clinical Drug Trials – current customers
Clinical Drug Trials – current customers For personal use only 5
Slide 6: Market Size: Clinical Trials
Market Size: Clinical Trials For personal use only Therapeutic Area Clinical Trials in Active Registration Average Number of New Clinical Trials (Phase I – IV) Started Per Year (based on 2008-2010 data) Cancer 3569 3319 Pain 2659 305 Depression 1392 305 Anxiety 1004 462 Sleep 934 367 Stroke 855 305
Slide 7: Clinical Drug Trials – current penetration
Clinical Drug Trials – current penetration For personal use only CogState currently signs 30-35 clinical trial contracts per year – a fraction of the available market. Given increasing scientific and commercial validation for the CogState system in a market where there is enormous scope for continue
Slide 8: Axon Sports
Axon Sports For personal use only Consumer market opportunity: use of CogState technology in the management of sports related concussion • Complete re-design of the technology to provide a web-based system • Partnered with experts in sports marketing in the USA : Rudy Chapa, previously global direct
Slide 9: Dementia Screening – early detection of AD
Dementia Screening – early detection of AD For personal use only • Alzheimer's disease and other dementias cover an estimated 35.6 million people - around 0.5% of the global population. • This figure is set to double in the next 20 years according to the World Alzheimer Report 2010 • In 2010, the gl
Slide 10: Dementia Screening – early detection of AD
Dementia Screening – early detection of AD For personal use only Deterioration of memory function in otherwise healthy older adults was associated with positive cerebral amyloid on PIB scanning (from Darby et al in press) The use of screening batteries with characteristics of the CogState battery in
Slide 11: Dementia Screening – early detection of AD
Dementia Screening – early detection of AD For personal use only • Completed validation of the CogState system for use in dementia screening programs • Studies have been completed correlating a decline in memory function with abnormally high levels of cerebral amyloid in a subgroup of otherwise heal
Slide 12: Conclusions
Conclusions For personal use only • Significant upside for CogState as we seek to expand our core clinical trial business – Significant scope for revenue growth within a niche market – Strong H2 FY11 and strong start to FY12 – Significant cost reduction implemented June 2012 – Improved financial per
Slide 13: Financial summary
Financial summary For personal use only FY 2011 Financial Summary Share summary (as of 30 Aug 2011) - Cash on hand A$3.3m - Shares Outstanding 74.6m - Loss from principal activities A$0.1m - Share Price A$0.17 - Net loss after tax A$0.8m - Market Cap A$13m - Revenues A$8.2m - Stock tightly held, top
Slide 14: Brad O'Connor, Chief Executive Officer
For personal use only Brad O’Connor Chief Executive Officer boconnor@cogstate.com